Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 1/2016

01-01-2016 | Gastrointestinal Cancers (J Meyer, Section Editor)

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors

Authors: Venkata K. Pokuri, Mei Ka Fong, Renuka Iyer

Published in: Current Oncology Reports | Issue 1/2016

Login to get access

Abstract

Neuroendocrine tumors are heterogeneous, rare malignancies that arise most commonly in the gastrointestinal tract and pancreas. They often secrete vasoactive substances resulting in carcinoid syndrome and the tumor cells exclusively express somatostatin receptors. Octreotide and lanreotide are the two synthetic somatostatin analogs used for the control of carcinoid symptoms and tumor progression in advanced inoperable disease. Recent pivotal trials (PROMID and CLARINET studies) established their antitumor activity. We discuss the available data to support their use as symptom controlling and antiproliferative agents. This article also reviews the guidelines (National Comprehensive Cancer Network and North American Neuro Endocrine Tumor Society), cost-analysis (suggesting the cost-effectiveness of lanreotide autogel compared to higher doses of octreotide long acting release formulation in refractory patients), and future directions of somatostatin analogs in the management of patients refractory to conventional doses of octreotide and lanreotide.
Literature
1.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRefPubMed
2.
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18. vii.CrossRef
3.
Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63.CrossRefPubMed
4.
Frilling A, Akerstrom G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19(5):R163–85.CrossRefPubMed
5.
Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbeck’s Arch Surg. 2011;396(3):273–98.CrossRef
6.
Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014;28(9):749–56. 758.
7.
Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47 Suppl 2:30–9.CrossRefPubMed
8.
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.CrossRefPubMed
9.••
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33. This is the phase 3 study establishing the anti-proliferative activity of Lanreotide, resulting in FDA approval of the first synthetic somatostatin analog for antitumor activity in gastro-entero-pancreatic neuroendocrine tumors.CrossRefPubMed
10.
Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 2004;80 Suppl 1:57–61.PubMed
11.
Meier RF, Reichert MM. Octreotide: a clinical update. Saudi J Gastroenterol. 1998;4(3):147–55.PubMed
12.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246–54.CrossRefPubMed
13.
14.
Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–6.CrossRefPubMed
15.
Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45(7):836–44.CrossRefPubMed
16.
Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600–6.PubMed
17.••
Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21(6):1945–55. This is a systematic review of all the studies which utilized higher than conventional doses of Octreotide LAR formulation. Despite wide use of these higher doses in clinical practice, there are no large, randomized trials proving their superiority over conventional doses of Octreotide LAR. This review summarizes the benefit of higher dose Octreotide LAR in carcinoid symptom control along with its antitumor efficacy.PubMedCentralCrossRefPubMed
18.
Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392–400.CrossRefPubMed
19.
Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39(2):279–83.PubMedCentralCrossRefPubMed
20.
Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88.PubMed
21.
O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–6.CrossRefPubMed
22.
Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87(1):99–104.CrossRefPubMed
23.
Lightman S. Somatuline autogel: an extended release lanreotide formulation. Hosp Med. 2002;63(3):162–5.CrossRefPubMed
24.
Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer. 2006;107(10):2474–81.CrossRefPubMed
25.
Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34(2):235–42.CrossRefPubMed
26.
Ruszniewski PCM, Valle J. Patient-reported satisfaction with symptom control during lanreotide Autogel/Depot treatment for carcinoid syndrome in gastroenteropancreatic neuroendocrine tumor patients: SymNET, a large multinational cross-sectional observational study. GI Cancers Symposium. 2014. Abstract No: 273.
27.
Vinik AWE, Audry H. ELECT: a phase III study of efficacy and safety of lanreotide Autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs). GI Cancers Symposium. 2014. Abstract No: 268.
28.
Strosberg JR, Fisher GA, Benson AB, et al. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas. 2013;42(3):397–404.CrossRefPubMed
29.
Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006;66(3):1576–82.CrossRefPubMed
30.
Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16(24):2963–70.PubMedCentralCrossRefPubMed
31.
Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13:822–40.CrossRefPubMed
32.
33.
Arnold RWM, Rinke A, Schade-Brittinger C, Aminossadati B. E R. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long-term survival. Proc Am Soc Clin Oncol. 2013;31. Abstr: 4030.
34.••
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. This article provides the guidelines (NANETS, North American Neuro Endocrine Tumor Society and NCCN, National Comprehensive Cancer Network) in the management of neuroendocrine tumors (NETs). Apart from identifying the applicability of synthetic somatostatin analogs in NETs, it also describe various other modalities of treatment for NETs and furnish guidelines to be used in day to day clinical practice.
35.••
Kulke MH, Shah MH, Benson 3rd AB, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13(1):78–108. This article provides the guidelines (NANETS, North American Neuro Endocrine Tumor Society and NCCN, National Comprehensive Cancer Network) in the management of neuroendocrine tumors (NETs). Apart from identifying the applicability of synthetic somatostatin analogs in NETs, it also describe various other modalities of treatment for NETs and furnish guidelines to be used in day to day clinical practice.
36.
Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440(5):461–75.CrossRefPubMed
37.
de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):451–8.CrossRefPubMed
38.
Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29(10):4127–30.PubMed
39.
Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas. 2011;40(7):987–94.CrossRefPubMed
40.
Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Investig. 2012;35(3):326–31.
41.
Edward M, Wolin MEC, Pavel ME, Cwikla JB, Phan AT, Markus R, et al. Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): subgroup analyses from the CLARINET study. J Clin Oncol. 2015;33 (suppl; abstr e15182).
42.
Nuria Buil-Bruna MJG, Marion D, Amandine M, Thi Xuan Quyen N, Gomez-Panzani EL, Troconiz IF. Population pharmacokinetic (PK) analysis of lanreotide autogel/depot in the treatment of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs): pooled analysis of four clinical trials. J Clin Oncol. 2015;33 suppl 3:abstr 397.
43.
Eugene Woltering MAS, Boudreaux JP, Wang Y-Z, Pam R, Uhlhorn AP, Mamikunian G. Effect of sex, weight, and body mass index on plasma lanreotide levels. J Clin Oncol. 2015;33 (suppl; abstr e15189).
44.
Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol. 2008;68(3):343–9.
45.
Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115–22.PubMedCentralCrossRefPubMed
46.
Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103–9.CrossRef
47.
Marty R, Roze S, Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices (Auckl). 2012;5:39–44.
48.
Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1–2):69–4.CrossRefPubMed
49.
Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–66.CrossRefPubMed
50.
Cives M, Kunz PL, Morse B, et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22(1):1–9.PubMedCentralCrossRefPubMed
51.
Wolin EM JB, Eriksson B, Walter T, Toumpanakis C, Morse MTP, Weber M, et al. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs [abstract]. In: 2013 American Society of Clinical Oncology Annual Meeting. J Clin Oncol. 2013;31(suppl):abstract 4031.
52.
Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–14.PubMedCentralCrossRefPubMed
53.
Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii124–30.PubMed
54.
Eriksson B, Kloppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87(1):8–19.CrossRefPubMed
55.
56.
Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol. 2004;61(2):224–31.CrossRef
57.
Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol. 2006;65(3):320–6.CrossRef
Metadata
Title
Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors
Authors
Venkata K. Pokuri
Mei Ka Fong
Renuka Iyer
Publication date
01-01-2016
Publisher
Springer US
Published in
Current Oncology Reports / Issue 1/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-015-0492-7

Other articles of this Issue 1/2016

Current Oncology Reports 1/2016 Go to the issue

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer

Breast Cancer (B Overmoyer, Section Editor)

The Epidemiology of Male Breast Cancer

Melanoma (RJ Sullivan, Section Editor)

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma

Leukemia (A Aguayo, Section Editor)

Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions

Gastrointestinal Cancers (J Meyer, Section Editor)

Robotic Surgery for Colon and Rectal Cancer

Palliative Medicine (A Jatoi, Section Editor)

State of the Art Antiemetic Therapy for Cancer Patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits